Owlet, Inc. (OWLT) Q3 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call highlights strong financial performance with record revenue and profit, despite tariff challenges. Positive guidance and strategic initiatives, such as international expansion and healthcare partnerships, bolster growth prospects. The Q&A reveals confidence in ongoing partnerships and market expansion, though some details, like subscriber retention, remain vague. Overall, the strong earnings and optimistic guidance, coupled with strategic partnerships, suggest a positive stock price movement.
Key Financial Performance
Q3 Revenue $32 million, increasing 45% versus Q3 2024. Revenue outperformance was driven by the launch of our new Dream Sight camera and ongoing momentum in the core business.
Q3 Gross Profit $16.2 million, resulting in Q3 gross margins of 50.6%. Top line strength was able to offset tariff impacts.
Q3 Adjusted EBITDA $1.6 million, a record for Owlet and the sixth consecutive quarter of adjusted EBITDA profitability.
Q3 Operating Income $1.2 million, the first quarterly operating profit in company history.
International Revenue Growth Up 171% year-over-year in Q3 2025. Driven by the launch of the new Dream Sight video monitor and ongoing momentum globally.
Domestic Sell-Through Growth 42% year-over-year in Q3 2025. Driven by ongoing adoption for Dream Sock and a record-setting Amazon Prime Day.
Net Income $4.1 million in Q3 2025 versus a $5.6 million net loss in Q3 2024. Includes a positive $4.3 million common stock warrant liability adjustment.
Cash and Cash Equivalents $23.8 million as of September 30, 2025, versus $21.8 million at the end of Q2 2025.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Launch of Dream Sight camera: Owlet introduced its third-generation video baby monitor, Dream Sight, featuring advanced technologies, enhanced security, and onboard AI capabilities. It pairs with Dream Sock for a connected monitoring experience.
Dream Sock adoption: Dream Sock demand grew significantly, with domestic sell-through increasing 42% year-over-year. It also achieved a record-setting Amazon Prime Day with a 72% increase in sell-through units.
Owlet360 subscription: Owlet360 subscription surpassed 85,000 paying subscribers, with plans to expand internationally in Q4 2025. Subscription attach rate for Dream Sock reached 25%.
AI and telehealth initiatives: Owlet plans to introduce AI-driven features for personalized sleep coaching in 2026 and is piloting a telehealth platform, Owlet OnCall, for remote care.
Market share growth: Owlet increased its share of total dollars spent on baby monitors to 40% in Q3 2025, a record high.
International expansion: International revenue grew 171% year-over-year, driven by the launch of Dream Sight and entry into new markets like India. Dream Sock now has regulatory clearance in six international markets.
Revenue growth: Q3 2025 revenue reached $32 million, a 45% increase from Q3 2024, driven by new product launches and subscription growth.
Profitability milestones: Owlet achieved its first quarterly operating profit of $1.2 million and its sixth consecutive quarter of adjusted EBITDA profitability.
FDA clearance advantage: Owlet's Dream Sock is the first FDA-cleared over-the-counter infant monitoring device, providing a competitive edge and reinforcing market leadership.
Healthcare channel expansion: Owlet launched a consignment agreement with a hospital for insurance-reimbursed monitoring and is integrating with digital health platforms to expand remote patient monitoring.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Tariff Costs: Tariff costs negatively impacted gross margin by 280 basis points in Q3 2025, with increased tariffs of 19% and 20% on imports from Thailand and Vietnam, respectively. This poses a financial challenge, especially during the crucial Q4 holiday sales period.
Regulatory and Compliance Risks: The FDA's recent safety communication on unauthorized infant monitors highlights the need for compliance with stringent regulatory standards. While Owlet's Dream Sock is FDA-cleared, maintaining compliance and addressing potential regulatory changes remain critical challenges.
Macroeconomic Uncertainty: The company faces risks from a challenging macroeconomic environment, including consumer uncertainty, potential government shutdown aftereffects, and tariff policies, which could impact Q4 holiday sales and overall financial performance.
Supply Chain and Operational Risks: Increased tariffs on imports from key manufacturing locations (Thailand and Vietnam) and potential supply chain disruptions could adversely affect production costs and product availability.
Strategic Execution Risks: The company is investing in R&D and expanding its subscription and healthcare offerings, but these initiatives require significant resources and precise execution to achieve profitability and market adoption.
Financial Risks: Despite raising $32 million in a follow-on equity offering, the company must manage its financial resources carefully to maintain profitability and fund growth initiatives, including R&D and international expansion.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Expectations: For the full year 2025, revenue is expected to be in the range of $103 million to $106 million, representing 32% to 36% growth year-over-year.
Gross Margin Projections: For 2025, gross margin is expected to be in the range of 48% to 50%, with Q4 impacted by increased tariff costs of 19%-20% on imports from Thailand and Vietnam, reducing margins by approximately 500 basis points.
Adjusted EBITDA: For the full year 2025, adjusted EBITDA is expected to be in the range of $1.25 million to $2 million, marking the first full year of adjusted EBITDA profitability.
Subscription Growth: Owlet360 subscriptions are expected to expand internationally in Q4 2025, starting with the U.K., Ireland, Australia, New Zealand, and South Africa, with further global expansion planned for 2026. Subscription attach rates for Dream Sock have surpassed 25%.
Product Development: In 2026, Owlet plans to introduce camera-based subscription features leveraging AI capabilities, including personalized sleep coaching and actionable insights for parents. A new telehealth platform, Owlet OnCall, is also set to launch in 2026.
International Expansion: Dream Sock has received regulatory approval for distribution in India, with sales expected to begin in early 2026. This adds to existing clearances in Europe, the U.K., Australia, New Zealand, South Africa, and the U.S.
Healthcare Channel Expansion: Owlet is expanding its healthcare channels with insurance-reimbursed monitoring devices. The first consignment agreement with a hospital has been launched, and further hospital partnerships are being explored.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What is the progress and experience with the partnership with Children's Hospital the King's Daughters (CHKD) in Virginia?
A:The partnership with CHKD is in its early stages, and the integration on the RPM has been successful. Both parties are happy with the progress, and the partnership is being used as a pilot for other healthcare systems. Conversations with other systems are ongoing, but no additional details are available yet.
Q:Which countries are experiencing the most international growth, and what markets are expected to drive growth through 2026?
A:International growth has been strong, with 171% growth in Q3. European countries are seeing sell-through growth, and new regulatory clearances, such as in India, are enabling global expansion. The third-generation Dream Sight and Dream Duo products have contributed to this momentum.
Q:How does the Rhapsody partnership enhance the value proposition of BabySat and the broader clinical platform for hospitals?
A:The Rhapsody integration, called Owlet Connect, provides neonatologists and hospitals with real-time access to BabySat data for babies discharged from the NICU. This integration allows for quicker scaling and implementation with other hospital systems, improving clinician engagement and streamlining processes.
Q:What are the trends in subscriber retention rates for Owlet360, and are there any new features driving engagement?
A:Subscriber retention rates are not disclosed, but engagement is strong. Owlet360, launched in January, is primarily based on Sock features, with plans to expand camera features, especially with the AI-enabled Dream Sight platform. Many users are requesting features similar to those of Oura Ring, indicating high engagement and potential for growth.
Q:Review of Unclear Management Responses
A:Management avoided providing specific details on subscriber churn rates for Owlet360, stating only that engagement is strong without offering numerical data or clear trends.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
AI capability
Australia New
CHKD
Dream Sight
Dream Sock
FDA warning
India
New Zealand
President CEO
RPM
Sight camera
Sock FDA
South Africa
Zealand South
adoption Dream
advantage
area progress
brand
camera subscription
care opportunity
clearance Dream
counter infant
generation
health care
infant monitor
infant monitoring
launch Dream
milestone
momentum core
monitoring device
nursery ecosystem
position market
record
share gain
subscription feature
video
OWLT Transcript
Owlet, Inc. (OWLT) Q1 2026 Earnings Call Transcript
Positive5-8
The earnings call highlights a positive outlook with record-high subscription revenue, improved gross margins, and strong international growth. Despite increased expenses, the company shows a strategic focus on high ROI initiatives and profitable growth. While operating losses widened, the adjusted EBITDA was at the higher end of guidance. The Q&A session provided clarity on cost management and strategic focus areas, with a strong emphasis on subscription and international expansion. Overall, the positive financial performance and strategic direction suggest a likely positive stock price movement in the short term.
Pro Real Estate Investment Trust (PRV.UN:CA) Q4 2025 Earnings Call Transcript
Positive3-5
The earnings call indicates strong financial performance with a 14.3% increase in FFO, reduced leverage, and strategic acquisitions. Management's focus on expanding in key markets and maintaining stable leasing spreads adds to the positive outlook. Although some responses were vague, the overall sentiment and financial metrics suggest a positive impact on stock price.
Owlet, Inc. (OWLT) Q4 2025 Earnings Call Transcript
Positive3-5
The earnings call highlights strong revenue growth, record high gross margins, and improved EBITDA, indicating operational efficiency. Positive sentiments arise from planned AI-driven product enhancements and international expansion. Although Q1 guidance is lower due to seasonality, the full-year outlook remains robust. The Q&A session reveals optimism in subscription growth and international expansion, despite management's reluctance to provide specific churn metrics. Given these factors, the stock price is likely to experience a positive movement, driven by strong financial performance and strategic growth initiatives.
Owlet, Inc. (OWLT) Q3 2025 Earnings Call Transcript
Positive11-13
The earnings call highlights strong financial performance with record revenue and profit, despite tariff challenges. Positive guidance and strategic initiatives, such as international expansion and healthcare partnerships, bolster growth prospects. The Q&A reveals confidence in ongoing partnerships and market expansion, though some details, like subscriber retention, remain vague. Overall, the strong earnings and optimistic guidance, coupled with strategic partnerships, suggest a positive stock price movement.
OWLT Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
